MétaCan
Menu
Back to cohort
Record W2133707964 · doi:10.1200/jco.2009.21.9022

Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment

2009· review· en· W2133707964 on OpenAlexaff
Philip A. Philip, Margaret Mooney, Deborah Jaffe, Gail Eckhardt, Malcolm J. Moore, Neal J. Meropol, Leisha A. Emens, Eileen M. O’Reilly, Murray Korc, Lee M. Ellis, Jacqueline Benedetti, Mace L. Rothenberg, Christopher G. Willett, Margaret A. Tempero, Andrew M. Lowy, James L. Abbruzzese, Diane M. Simeone, Sunil R. Hingorani, Jordan Berlin, Joel E. Tepper

Bibliographic record

VenueJournal of Clinical Oncology · 2009
Typereview
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsOntario Institute for Cancer Research
FundersNational Cancer Institute
KeywordsMedicineClinical trialPancreatic cancerCancerClinical endpointOncologyPancreatic ductal adenocarcinomaClinical study designDiseaseInternal medicine

Abstract

fetched live from OpenAlex

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.045
metaresearch head score (Gemma)0.106
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (broad), Research integrity
Consensus categoriesMetaresearch, Research integrity
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.942
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0450.106
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0160.005
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.776
GPT teacher head0.710
Teacher spread0.065 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations249
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicPancreatic and Hepatic Oncology ResearchFrench-language works237,207